CD274 and non-small cell lung carcinoma: As reported in registrative clinical trials, the median PFS of pembrolizumab as monotherapy in PD-L1 overexpressed patients is 10.3 months (7–9) and 8.8 months (5, 10) when used in combination with chemotherapy for non-squamous NSCLC.